Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Pipeline Review, H1 2016

  • ID: 3802766
  • Drug Pipelines
  • 43 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Atlantic Healthcare Plc
  • DiNonA Inc.
  • MingSight Pharmaceuticals
  • MORE
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Pipeline Review, H1 2016

Summary

‘Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Pipeline Review, H1 2016’, provides in depth analysis on Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted pipeline therapeutics.

The report provides comprehensive information on the Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54)
- The report reviews Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted therapeutics and enlists all their major and minor projects
- The report assesses Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Atlantic Healthcare Plc
  • DiNonA Inc.
  • MingSight Pharmaceuticals
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Overview

Therapeutics Development

Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under Development by Stage of Development

Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under Development by Therapy Area

Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under Development by Indication

Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under Development by Companies

Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under Development by Universities/Institutes

Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Companies Involved in Therapeutics Development

Atlantic Healthcare Plc

China Medical System Holdings Limited

DiNonA Inc.

MingSight Pharmaceuticals

RXi Pharmaceuticals Corporation

Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Drug Profiles

alicaforsen sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMS-024 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNP-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melittin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MS-553 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Inhibit Fibrinogen and ICAM-1 for Oncology, Immunology, Cardiovascular, Musculoskeletal and Hematological Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RNAi Oligonucleotide to Inhibit ICAM-1 for Retinal Diseases and Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Dormant Projects

Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Discontinued Products

Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Featured News & Press Releases

Feb 11, 2016: Atlantic Healthcare starts pivotal Phase 3 trial of Alicaforsen to treat Inflammatory Bowel Disease Pouchitis

Jan 28, 2011: CMS Expects To Launch CMS024 For Treatment Of Primary Liver Carcinoma Three Years Ahead Of Plan In 2013

Jul 08, 2008: FDA Grants Orphan Drug Designation For Alicaforsen

Dec 02, 2004: Isis Pharmaceuticals Announces Phase 3 Clinical Trials Results Of Alicaforsen With Crohn's Disease

Dec 02, 2004: Isis Pharmaceuticals Inc. Announces Phase II clinical Trials Of Alicaforsen For Ulcerative Colitis

Apr 08, 2003: Isis Pharmaceuticals Initiates Additional Phase II Clinical Trial Of Alicaforsen, ISIS 2302, In Patients With Ulcerative Colitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 43List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Atlantic Healthcare Plc, H1 2016

Pipeline by China Medical System Holdings Limited, H1 2016

Pipeline by DiNonA Inc., H1 2016

Pipeline by MingSight Pharmaceuticals, H1 2016

Pipeline by RXi Pharmaceuticals Corporation, H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 36List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Atlantic Healthcare Plc
  • DiNonA Inc.
  • MingSight Pharmaceuticals
  • MORE
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Intercellular Adhesion Molecule 1 (ICAM-1) is a protein encoded by the ICAM1 gene. It acts as a receptor for major receptor group rhinovirus A-B capsid proteins and Coxsackievirus A21 capsid proteins. ICAM1 promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation.

Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

The author's latest report Intercellular Adhesion Molecule 1 - Pipeline Review, H1 2016, outlays comprehensive information on the Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Atlantic Healthcare Plc
China Medical System Holdings Limited
DiNonA Inc.
MingSight Pharmaceuticals
RXi Pharmaceuticals Corporation
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll